Medetomidine is now in more than a third of Philadelphia’s opioid samples

What the data shows

A veterinary sedative roughly 200 times more potent than xylazine is becoming a structural feature of the unregulated opioid supply. Philadelphia drug-checking samples tracked by the city’s Department of Public Health showed medetomidine in 4% of opioid samples in May 2024 and 37% by October 2025. National forensic reporting tells the same story at a larger scale: NFLIS recorded 247 medetomidine identifications in 2023, 2,616 in 2024, and 8,233 in 2025 — a 33-fold increase across two years.

The clinical implications are the part most people miss. Medetomidine doesn’t respond predictably to naloxone, so a reversal can leave a person breathing again but profoundly sedated and at risk for re-overdose. Withdrawal is the second complication: medetomidine withdrawal, as the Pharmacy Times clinical review notes, can include severe hypertension, agitation, and risk of cardiac complications — and unlike xylazine, abrupt cessation can be life-threatening.

Why it matters

The 17%+ overdose decline through 2025 is real, but it’s a denominator-and-numerator story. Fewer people are using the supply, and naloxone is reaching more of those who do. The composition of the supply itself, however, is moving in a direction that makes future overdoses harder to reverse and post-discharge care harder to deliver. The CDC’s Health Alert Network notice from late 2024 flagged exactly this risk; the 2025 numbers are confirming it.

For people in recovery, especially those returning to use after a period of reduced tolerance: the supply you encounter today is chemically different from the one you encountered two years ago. Talk to a clinician, carry naloxone, and if you’re considering treatment, find help here.